Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) - Total Assets

Latest as of March 2026: CN¥14.18 Billion CNY ≈ $2.07 Billion USD

Based on the latest financial reports, Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) holds total assets worth CN¥14.18 Billion CNY (≈ $2.07 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Shijiazhuang Yiling Pharmaceutical Co Ltd - Total Assets Trend (2008–2025)

This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Shijiazhuang Yiling Pharmaceutical Co Lt (002603) market capitalisation for the company's overall valuation and market capitalisation.

Shijiazhuang Yiling Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Shijiazhuang Yiling Pharmaceutical Co Ltd's total assets of CN¥14.18 Billion consist of 38.1% current assets and 61.9% non-current assets. Review 002603 total debt and obligations to assess the company's total debt and financial obligations.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 8.1%
Accounts Receivable CN¥1.23 Billion 9.0%
Inventory CN¥1.49 Billion 10.9%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥1.05 Billion 7.7%
Goodwill CN¥103.28 Million 0.8%

Asset Composition Trend (2008–2025)

This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Shijiazhuang Yiling Pharmaceutical Co Lt for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Shijiazhuang Yiling Pharmaceutical Co Ltd's current assets represent 38.1% of total assets in 2025, a decrease from 53.6% in 2008.
  • Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 15.2% in 2008.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 3.0% in 2008.
  • Asset Diversification: The largest asset category is inventory at 10.9% of total assets.

Shijiazhuang Yiling Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Shijiazhuang Yiling Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Sweden Skr81.26 Billion
Yunnan Baiyao Group Co Ltd
SHE:000538
China CN¥53.34 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Harbin Gloria Pharmaceuticals
SHE:002437
China CN¥3.14 Billion
Jiuzhitang Co Ltd
SHE:000989
China CN¥5.73 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion

Shijiazhuang Yiling Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.50 1.80 1.58
Quick Ratio 1.92 1.28 1.15
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥3.47 Billion CN¥2.13 Billion CN¥2.71 Billion

Shijiazhuang Yiling Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Shijiazhuang Yiling Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.48
Latest Market Cap to Assets Ratio 0.27
Asset Growth Rate (YoY) 2.7%
Total Assets CN¥13.67 Billion
Market Capitalization $3.72 Billion USD

Valuation Analysis

Below Book Valuation: The market values Shijiazhuang Yiling Pharmaceutical Co Ltd's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Shijiazhuang Yiling Pharmaceutical Co Ltd's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2025)

The table below shows the annual total assets of Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2025.

Year Total Assets Change
2025-12-31 CN¥13.67 Billion
≈ $2.00 Billion
+2.67%
2024-12-31 CN¥13.32 Billion
≈ $1.95 Billion
-21.56%
2023-12-31 CN¥16.98 Billion
≈ $2.48 Billion
+3.91%
2022-12-31 CN¥16.34 Billion
≈ $2.39 Billion
+26.62%
2021-12-31 CN¥12.90 Billion
≈ $1.89 Billion
+12.14%
2020-12-31 CN¥11.51 Billion
≈ $1.68 Billion
+26.89%
2019-12-31 CN¥9.07 Billion
≈ $1.33 Billion
+5.99%
2018-12-31 CN¥8.56 Billion
≈ $1.25 Billion
+8.49%
2017-12-31 CN¥7.89 Billion
≈ $1.15 Billion
+26.04%
2016-12-31 CN¥6.26 Billion
≈ $915.73 Million
+9.65%
2015-12-31 CN¥5.71 Billion
≈ $835.11 Million
+12.17%
2014-12-31 CN¥5.09 Billion
≈ $744.52 Million
+9.23%
2013-12-31 CN¥4.66 Billion
≈ $681.62 Million
+11.82%
2012-12-31 CN¥4.17 Billion
≈ $609.58 Million
-1.41%
2011-12-31 CN¥4.23 Billion
≈ $618.31 Million
+138.57%
2010-12-31 CN¥1.77 Billion
≈ $259.17 Million
+17.34%
2009-12-31 CN¥1.51 Billion
≈ $220.88 Million
+81.44%
2008-12-31 CN¥831.91 Million
≈ $121.73 Million
--

About Shijiazhuang Yiling Pharmaceutical Co Ltd

SHE:002603 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.72 Billion
CN¥25.39 Billion CNY
Market Cap Rank
#4317 Global
#675 in China
Share Price
CN¥15.20
Change (1 day)
+0.53%
52-Week Range
CN¥14.66 - CN¥21.05
All Time High
CN¥1254.44
About

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and pers… Read more